Comparison
LL-37 vs. Sekretin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
597562-32-8
no data
Molecular weight
4493.33 g/mol
3055.5 g/mol
Half-life
no data
no data
Sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESno data
Mechanism of action
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Sekretin
Secretin binds the Gs-coupled secretin receptor (SCTR) on pancreatic duct cells, opens CFTR chloride channels and triggers secretion of bicarbonate-rich pancreatic fluid and bile flow.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
0
of which in humans
1
0
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
0
1
Legal status
Full entries
Frequently asked questions
- What is the difference between LL-37 and Sekretin?
- LL-37 is classified as "Research other", while Sekretin is classified as "Research other". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Sekretin: Secretin is a 27-amino-acid hormone that regulates pancreatic bicarbonate secretion. As ChiRhoStim it is FDA-approved as a diagnostic agent (pancreatic function test, gastrinoma test, secretin-enhanced MRCP). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Sekretin?
- The highest available evidence level is "Human trial" for LL-37 and "Human trial" for Sekretin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Sekretin in Germany and the United States?
- Germany: LL-37 — Research only, Sekretin — Prescription. United States: LL-37 — Research only, Sekretin — Prescription. These are factual summaries with source and review date on the individual pages.